Carisma Therapeutics Files 8-K: Other Events & Financials

TL;DR

CARisma filed an 8-K today covering other events and financials. Keep an eye on this.

AI Summary

On June 27, 2024, Carisma Therapeutics Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant business occurrences. The company, formerly known as Sesen Bio, Inc. and Eleven Biotherapeutics, Inc., is incorporated in Delaware and based in Philadelphia, PA.

Why It Matters

This 8-K filing signals that Carisma Therapeutics Inc. has made significant disclosures regarding its operations or financial condition, which could impact investor understanding of the company's current status.

Risk Assessment

Risk Level: medium — 8-K filings can contain material information, but the specific details of 'Other Events' and 'Financial Statements' require further analysis to determine the precise risk implications.

Key Players & Entities

• Carisma Therapeutics Inc. (company) — Registrant
• Sesen Bio, Inc. (company) — Former Company Name
• Eleven Biotherapeutics, Inc. (company) — Former Company Name
• June 27, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value CARM The Nasdaq Stock Mar
• $2 million — nited States. The nomination triggers a $2 million milestone payment to the Company. A co

Filing Documents

• tm2418383d1_8k.htm (8-K) — 27KB
• tm2418383d1_ex99-1.htm (EX-99.1) — 13KB
• tm2418383d1_ex99-1img001.jpg (GRAPHIC) — 12KB
• 0001104659-24-075709.txt ( ) — 231KB
• carm-20240627.xsd (EX-101.SCH) — 3KB
• carm-20240627_lab.xml (EX-101.LAB) — 33KB
• carm-20240627_pre.xml (EX-101.PRE) — 22KB
• tm2418383d1_8k_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. On June 27, 2024, Carisma Therapeutics Inc. (the "Company") announced that it received notice from ModernaTX, Inc. ("Moderna") that Moderna had nominated the first development candidate (the "Development Candidate") under the Collaboration and License Agreement, dated January 7, 2022, by and between the Company and Moderna. The Development Candidate is an in vivo chimeric antigen receptor macrophage targeting Glypican-3 and is designed to treat solid tumors, including hepatocellular carcinoma, the most prevalent type of liver cancer and the fastest-rising cause of cancer-related death in the United States. The nomination triggers a $2 million milestone payment to the Company. A copy of the Company's press release announcing the nomination of the Development Candidate is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release issued by Carisma Therapeutics Inc. on June 27, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARISMA THERAPEUTICS INC. By : /s/ Steven Kelly Date: June 27, 2024 Steven Kelly President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR